AbbVie is trading 3.04% up at $266.79 as healthcare stocks rally, investors rotate toward defensive growth, and sector earnings outlooks improve.
- No fresh company-specific announcement clearly explains the August 19, 2026 move.
- Wells Fargo raised its price target to $300 from $295 while maintaining an Overweight rating.
- The firm cited AbbVie’s potential in hidradenitis suppurativa; evidence points primarily to sector-led buying.